Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Bond & Taylor Wants to Hear from Consumers Who Have Suffered Xarelto® Blood Thinner Injury


Print article Print article
2012-11-14 20:50:20 - The product liability law firm of Bond & Taylor wants to talk to consumers who have suffered blood thinner injury taking the blood thinner medication Xarelto®. Consumers who have suffered these blood thinner injuries are encouraged to call the firm for a free consultation.

The product liability law firm of Bond & Taylor announced today that they would like to speak to consumers who have suffered blood thinner injuries taking Xarelto®. Consumers who have experienced severe hemorrhages, abnormal kidney or liver functions, severe allergic reactions and other blood thinner injuries are encouraged to call the firm today for a free consultation.

Xarelto® (Rivaroxaban) is a blood thinner medication prescribed to patients with atrial fibrillation, the most common form of cardiac arrhythmia. This condition affects an estimated 3 million Americans and 15% of elderly Americans over the age of 80. In these patients, there is a significant increased risk for developing a blood clot in the heart due to blood pooling in a storage chamber

of the heart. This clotted blood can travel to the brain and block an artery supplying blood to the brain, causing a stroke.

The FDA recently approved Xarelto® as a blood thinner medication to prevent blood clots, but within the first 3 months, over 356 adverse health effects were reported. The most common of these adverse health effects were hemorrhaging or heavy internal bleeding. According to the Institute for Safe Medicine Practices, Xarelto® is as risky as Pradaxa® because both thrombin inhibitors lack a reversal agent to stop potentially fatal bleeding events. ( www.ismp.org/tools/highalertmedications.pdf)

In 2011, the FDA reported the highest amount of prescription medication deaths last year were due to Pradaxa®. This popular blood thinner allegedly caused severe blood thinner injuries for nearly 4,000 people and over 500 deaths. Many doctors have expressed fears that because of the similarities between Pradaxa® and Xarelto®, patients are at severe risk for potentially fatal bleeding and severe blood thinner injury. ( www.huffingtonpost.com/2012/06/14/pradaxa-xarelto-blood-thinner- ..)

Patients who have suffered blood thinner injury due to Xarelto® are encouraged to call the product liability law firm of Bond & Taylor today. Said partner Andrew L. Wright, “We’d like to reach out to those who have been injured taking Xarelto® and may be seeking help for their blood thinner injuries.”

About Bond & Taylor:

Extensive product liability experience gives Andrew L. Wright the expertise necessary to handle your defective prescription drug case. With over 20 years of experience as a trial lawyer, Andrew L. Wright is used to standing up for his clients and achieving results.

The law firm of Bond & Taylor has over 30 years of experience fighting zealously on behalf of injured clients and grieving family members who have lost a loved one due to negligence. The firm prides itself on being experts at fighting to achieve the fairness and justice clients deserve. Attorneys at Bond & Taylor are passionate advocates for their clients who treat clients with the compassion and respect they deserve. The attorneys at Bond & Taylor understand clients and their families are suffering and want to fight for the compensation that clients deserve. Cases are accepted nationwide; call the firm of Bond & Taylor for a free confidential consultation at (800) 471-0314. www.bondtaylorlaw.com





Press Information:
Bond & Taylor

17500 Red Hill Ave. #100
Irvine, CA 92614

Contact Person:
Catherine
Director of Public Relations
Phone: (949) 988-7100
email: email

Web: www.bondtaylorlaw.com

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser